FindTrial
Sign In

A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Co-administration Of Ezetimibe 10 Mg With Ongoing Treatment with Simvastatin 20 Mg Versus Doubling The Dose of Simvastatin In Subjects With Primary Hypercholesterolemia Diabetes Mellitus Type 2 And Coronary Heart Disease

A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Co-administration Of Ezetimibe 10 Mg With Ongoing Treatment with Simvastatin 20 Mg Versus Doubling The Dose of Simvastatin In Subjects With Primary Hypercholesterolemia Diabetes Mellitus Type 2 And Coronary Heart Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002236-26-IT
Enrollment
Unknown
Registered
2005-08-01
Start date
2005-01-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hypercholesterolemia MedDRA version: 6.1 Level: HLGT Classification code 10013317

Interventions

Trade Name: Ezetrol Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Ezetimibe Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-

Sponsors

SCHERING-PLOUGH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026